Thierry André

Research interests

Publications

• Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

  JAMA Oncology · 2022 · https://doi.org/10.1001/jamaoncol.2022.3829

• Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study

  The Lancet Oncology · 2022 · 10.1016/s1470-2045(22)00197-8

• Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(20)30527-1

• Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2017699

• Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164

  Journal of Clinical Oncology · 2019 · 10.1200/jco.19.02107

• 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30336-5

• Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2018 · https://doi.org/10.1200/jco.2017.76.9901

• Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

  New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1713709

• Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

  The Lancet Infectious Diseases · 2017 · https://doi.org/10.1016/s1473-3099(16)30521-7

• Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas

  The Journal of Pathology · 2017 · https://doi.org/10.1002/path.4880

• Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30422-9

• Analysis of KRAS / NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

  Clinical Cancer Research · 2015 · https://doi.org/10.1158/1078-0432.ccr-15-0526

• Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70212-8

• Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer

  Annals of Oncology · 2013 · https://doi.org/10.1093/annonc/mdt523

• Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

  Gastroenterology · 2012 · https://doi.org/10.1053/j.gastro.2012.06.006

• Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

  The Lancet Oncology · 2012 · 10.1016/s1470-2045(12)70477-1

• Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.27.6055

• Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.6771

• Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.21.6663

• KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2007.12.5906

• Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2007 · https://doi.org/10.1200/jco.2007.13.2183

• OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.03.0106

• Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.06.023

• Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer

  New England Journal of Medicine · 2004 · https://doi.org/10.1056/nejmoa032709

• FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

  Journal of Clinical Oncology · 2003 · https://doi.org/10.1200/jco.2004.05.113

• Phase II Study of Oxaliplatin, Fluorouracil, and Folinic Acid in Locally Advanced or Metastatic Gastric Cancer Patients

  Journal of Clinical Oncology · 2002 · https://doi.org/10.1200/jco.2002.02.021

• Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

  Journal of Clinical Oncology · 1999 · https://doi.org/10.1200/jco.1999.17.11.3560

Current projects

No projects listed.